Samsung Electronics Shares Jump on HBM4 Mass Production Report 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
LOS ANGELES, Aug. 28, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL) regarding possible violations of federal securities laws from May 5, 2017 through July 6, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired Ocular shares during the Class Period should contact the firm before the September 5, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may choose to do nothing and be an absent class member as well.
According to the Complaint, during the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company’s management misled investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by Ocular contain bad product; that these manufacturing issues could endanger the approval of DEXTENZA by the FDA; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this information reached the public, shares of Ocular lowered in value materially, which caused investors harm according to the lawsuit.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles, dedicated to upholding shareholders’ rights.
This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
